- Email: [email protected]
Vascular targeted photodynamic therapy with WST-11 (TOOKAD®) soluble in oncology: Worldwide clinical overview in focal treatment in prostate cancer
Abstracts / Photodiagnosis and Photodynamic Therapy 12 (2015) 325–375
Moderate pain was reported at 5, 10, 15, 20, 25, 30, 35, 40 min for 35%, 38.7%, 46,25%, 40%, 43,70%, 45%, 36,25%, and 35% of patients, respectively. Only one patient had absence of pain during treatment. During all irradiation 16 patients (20%) were classified as mild pain, 57.5% as moderate and 22.5% as severe pain. In this study, most of pain was classified as moderate despite using a large area device. http://dx.doi.org/10.1016/j.pdpdt.2015.07.013 Vascular targeted photodynamic therapy with WST-11 (TOOKAD® ) soluble in oncology: Worldwide clinical overview in focal treatment in prostate cancer Paulo Palma 1 , Fawzi Benzaghou 2 , Ramon Rodriguez Lay 3 , Luis Zeggara 4 , Abderrahmène Azzouzi 5 , Arturo Rodriguez Rivera 6 1
University Hospital (UNICAMP), Campinas, Brazil Medical Department Stebabiotech, Paris, France 3 University Hospital, Panama City, Panama 4 University Hospital, Lima, Peru 5 University Hospital, Angers, France 6 University Hospital, Guadalaraja, Mexico
327
could be considered for the treatment of small superficial lung cancer. We retrospectively reviewed 24 patients with early lung cancer who underwent PDT between 2006 and 2014 at a tertiary hospital in Seoul, Korea. Complete remission was defined as no malignant cells from either bronchoscopic biopsy or washing cytology. All patients were male and median age was 69 (range: 54–76). All were diagnosed with stage IA squamous cell carcinoma and most had underlying cardiorespiratory insufficiency (33.3%) or synchronous multiple bronchial lesion (29.2%) which preclude surgery. Photofrin® (2 mg/kg) was intravenously administered as a photosensitizer and PDT was performed with Ceralas diode laser system (630 nm). Following PDT, complete remission was achieved in 18 (75.0%) patients and there were no cases of acute and chronic complication related to PDT. During median follow-up of 23.5 months, median overall survival was 37.2 months (95% CI: 12.3–62.1 months) and median recurrence-free survival was 21.0 months (95% CI: 0–48.2 months). Although surgery is the standard treatment for early lung cancer, PDT could be an effective alternative for treatment of early lung cancer.
2
WST11 (TOOKAD® Soluble) VTP in prostate cancer is a focal minimally invasive therapy that allows treating only the part of the prostate where the tumor was located while avoiding unnecessary radical prostatectomies and their noxious consequences as erectile dysfunction and urinary incontinence. The procedure is performed in the operating room under general anesthesia. It consists in the intravascular administration of the photosensitizer (WST11) to the patient, the drug is activated by light diffusing optical fibers inserted transperineally inside the prostate under ultrasound guidance to target the focus. The optimal conditions have been defined: 4 mg/patient kg, 200 J/cm and Light Density Index (LDI) > with more than 80% of negative biopsy in the treated lobe. The necrosis can be evaluated at Day 7 post therapy by MRI. During this medical overview, we present the clinical results of the VTP therapy in term of efficacy (prostate biopsy) and safety (erectile function, urinary continence and quality of life) in Europe, US and Latin America. http://dx.doi.org/10.1016/j.pdpdt.2015.07.014 Clinical experience and outcome of photodynamic therapy in early lung cancer Bo young Lee 1 , Jae Cheol Lee 2 , Hyeong Ryul Kim 3 , Seung Hun Jang 4 , Chang-Min Choi 1 1 Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 2 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Division of Thoracic Surgery, Seoul, Republic of Korea 3 Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 4 Division of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea
Lung cancer is a leading cause of cancer-related death worldwide. When surgery is not amenable, photodynamic therapy (PDT)
http://dx.doi.org/10.1016/j.pdpdt.2015.07.015 Evaluation of photodynamic therapy with talaporfin sodium on relapse controlling efficacy at laser irradiation sites in newly diagnosed glioblastoma Takashi Maruyama, Soko Ikuta, Masayuki Nitta, Yoshihiro Muragaki, Hiroshi Iseki Department of Neurosurgery, Tokyo Women’s Medical University, Japan Improvement of local control by PDT would be expected to result in prolongation of survival and tumor progression. In 11 newly diagnosed GBM cases, a single intravenous injection of talaporfin sodium (40 mg/m2 ) was administered one day before tumor removal. Target area was irradiated with 664 nm semiconductor laser with a radiation power density of 150 mW/cm2 and a radiation energy density of 27 J/cm2 . The target location was recorder on update navigation image using intraoperative MRI. OS, PFS, local PFS such as recurrence within irradiation site and recurrence pattern of PDT irradiation site, in-GTV margin-field, distant and dissemination were monitored. Results: Median survival time, median progression free survival and median local PFS were 31.5 m, 19.6 m and did not reached, respectively. Among 10 patients, central relapse include one within PDT irradiation field, in GTV margin-field, and distant location were 4 cases (40%), 2 cases (20%) and 4 (40%). MST of patient relapsed within central and/or in GTV margin-field and distant location were 22.1 m and 34.8 m. Radiographicial changes were observed in 13 sites (59%) in 9 cases. The depth of penetration average was 11 mm (4.7–21.6 mm). PDT using talaporfin sodium was well tolerable and showed good local control rate. http://dx.doi.org/10.1016/j.pdpdt.2015.07.016
Moderate pain was reported at 5, 10, 15, 20, 25, 30, 35, 40 min for 35%, 38.7%, 46,25%, 40%, 43,70%, 45%, 36,25%, and 35% of patients, respectively. Only one patient had absence of pain during treatment. During all irradiation 16 patients (20%) were classified as mild pain, 57.5% as moderate and 22.5% as severe pain. In this study, most of pain was classified as moderate despite using a large area device. http://dx.doi.org/10.1016/j.pdpdt.2015.07.013 Vascular targeted photodynamic therapy with WST-11 (TOOKAD® ) soluble in oncology: Worldwide clinical overview in focal treatment in prostate cancer Paulo Palma 1 , Fawzi Benzaghou 2 , Ramon Rodriguez Lay 3 , Luis Zeggara 4 , Abderrahmène Azzouzi 5 , Arturo Rodriguez Rivera 6 1
University Hospital (UNICAMP), Campinas, Brazil Medical Department Stebabiotech, Paris, France 3 University Hospital, Panama City, Panama 4 University Hospital, Lima, Peru 5 University Hospital, Angers, France 6 University Hospital, Guadalaraja, Mexico
327
could be considered for the treatment of small superficial lung cancer. We retrospectively reviewed 24 patients with early lung cancer who underwent PDT between 2006 and 2014 at a tertiary hospital in Seoul, Korea. Complete remission was defined as no malignant cells from either bronchoscopic biopsy or washing cytology. All patients were male and median age was 69 (range: 54–76). All were diagnosed with stage IA squamous cell carcinoma and most had underlying cardiorespiratory insufficiency (33.3%) or synchronous multiple bronchial lesion (29.2%) which preclude surgery. Photofrin® (2 mg/kg) was intravenously administered as a photosensitizer and PDT was performed with Ceralas diode laser system (630 nm). Following PDT, complete remission was achieved in 18 (75.0%) patients and there were no cases of acute and chronic complication related to PDT. During median follow-up of 23.5 months, median overall survival was 37.2 months (95% CI: 12.3–62.1 months) and median recurrence-free survival was 21.0 months (95% CI: 0–48.2 months). Although surgery is the standard treatment for early lung cancer, PDT could be an effective alternative for treatment of early lung cancer.
2
WST11 (TOOKAD® Soluble) VTP in prostate cancer is a focal minimally invasive therapy that allows treating only the part of the prostate where the tumor was located while avoiding unnecessary radical prostatectomies and their noxious consequences as erectile dysfunction and urinary incontinence. The procedure is performed in the operating room under general anesthesia. It consists in the intravascular administration of the photosensitizer (WST11) to the patient, the drug is activated by light diffusing optical fibers inserted transperineally inside the prostate under ultrasound guidance to target the focus. The optimal conditions have been defined: 4 mg/patient kg, 200 J/cm and Light Density Index (LDI) > with more than 80% of negative biopsy in the treated lobe. The necrosis can be evaluated at Day 7 post therapy by MRI. During this medical overview, we present the clinical results of the VTP therapy in term of efficacy (prostate biopsy) and safety (erectile function, urinary continence and quality of life) in Europe, US and Latin America. http://dx.doi.org/10.1016/j.pdpdt.2015.07.014 Clinical experience and outcome of photodynamic therapy in early lung cancer Bo young Lee 1 , Jae Cheol Lee 2 , Hyeong Ryul Kim 3 , Seung Hun Jang 4 , Chang-Min Choi 1 1 Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 2 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Division of Thoracic Surgery, Seoul, Republic of Korea 3 Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 4 Division of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea
Lung cancer is a leading cause of cancer-related death worldwide. When surgery is not amenable, photodynamic therapy (PDT)
http://dx.doi.org/10.1016/j.pdpdt.2015.07.015 Evaluation of photodynamic therapy with talaporfin sodium on relapse controlling efficacy at laser irradiation sites in newly diagnosed glioblastoma Takashi Maruyama, Soko Ikuta, Masayuki Nitta, Yoshihiro Muragaki, Hiroshi Iseki Department of Neurosurgery, Tokyo Women’s Medical University, Japan Improvement of local control by PDT would be expected to result in prolongation of survival and tumor progression. In 11 newly diagnosed GBM cases, a single intravenous injection of talaporfin sodium (40 mg/m2 ) was administered one day before tumor removal. Target area was irradiated with 664 nm semiconductor laser with a radiation power density of 150 mW/cm2 and a radiation energy density of 27 J/cm2 . The target location was recorder on update navigation image using intraoperative MRI. OS, PFS, local PFS such as recurrence within irradiation site and recurrence pattern of PDT irradiation site, in-GTV margin-field, distant and dissemination were monitored. Results: Median survival time, median progression free survival and median local PFS were 31.5 m, 19.6 m and did not reached, respectively. Among 10 patients, central relapse include one within PDT irradiation field, in GTV margin-field, and distant location were 4 cases (40%), 2 cases (20%) and 4 (40%). MST of patient relapsed within central and/or in GTV margin-field and distant location were 22.1 m and 34.8 m. Radiographicial changes were observed in 13 sites (59%) in 9 cases. The depth of penetration average was 11 mm (4.7–21.6 mm). PDT using talaporfin sodium was well tolerable and showed good local control rate. http://dx.doi.org/10.1016/j.pdpdt.2015.07.016